Provided by Tiger Trade Technology Pte. Ltd.

Alkermes PLC

49.21
+0.34000.70%
Post-market: 49.210.00000.00%16:10 EDT
Volume:1.04M
Turnover:50.97M
Market Cap:8.26B
PE:126.75
High:49.58
Open:48.94
Low:48.87
Close:48.87
52wk High:55.67
52wk Low:25.17
Shares:167.76M
Float Shares:155.00M
Volume Ratio:0.81
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3882
EPS(LYR):1.43
ROE:3.85%
ROA:4.20%
PB:4.56
PE(LYR):34.41

Loading ...

Alkermes - Alixorexton Shows Sustained Improvement on Mwt and ESS at Week 24, Nine Months After First Dose

THOMSON REUTERS
·
Jul 13

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults with Narcolepsy Type 1 and Type 2 in Long-term Extension Study Interim Analysis

THOMSON REUTERS
·
Jul 13

Bank of America Securities Remains a Sell on Alkermes (ALKS)

TIPRANKS
·
Jul 13

Alkermes Plc : JP Morgan Resumes Coverage with Neutral Rating; Target Price $60

THOMSON REUTERS
·
Jul 13

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Immunome (IMNM)

TIPRANKS
·
Jul 09

Is Alkermes (ALKS) Fully Priced As Russell 2000 Index Inclusion Draws Fresh Attention?

Simply Wall St.
·
Jul 09

Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolus (EOLS), Alkermes (ALKS) and VolitionRX (VNRX)

TIPRANKS
·
Jul 08

Alkermes - no Penalties or Further Obligations Owed by Alkermes or Amneal After Agreement Termination - SEC Filing

THOMSON REUTERS
·
Jul 08

Alkermes - Co and Amneal Terminate Authorized Generic Product Supply Agreement on July 6, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 08

Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $109,882.02

Reuters
·
Jul 07

The Bull Case For Alkermes (ALKS) Could Change Following Vibrance-12 Data And Russell 2000 Inclusion

Simply Wall St.
·
Jul 04

Alkermes (ALKS) Gets a Buy from Mizuho Securities

TIPRANKS
·
Jul 02

Alkermes EVP R&D and Chief Medical Officer Craig C. Hopkinson Disposes of USD 463,233 in Common Shares

Reuters
·
Jul 02

Alkermes Faces Risk on Orexin-Related Value From Upcoming Updates, BofA Says

MT Newswires Live
·
Jun 29

Alkermes Cut to Underperform from Neutral by B of a Securities

Dow Jones
·
Jun 29

BofA Securities Downgrades Alkermes to Underperform From Neutral, $38 Price Target

MT Newswires Live
·
Jun 29

Alkermes downgraded to Underperform from Neutral at BofA

TIPRANKS
·
Jun 29

Wells Fargo Keeps Their Buy Rating on Alkermes (ALKS)

TIPRANKS
·
Jun 29

Europe Research Roundup-ashmore, Flughafen, Richemont

Reuters
·
Jun 29

Movement Alert|Alkermes Rises 6.97% in Regular Trading, Narcolepsy Drug Phase 2 Trial Meets Dual Primary Endpoints and Advances to Phase 3

Market Focus
·
Jun 25